Fixed-dose combination therapy for the prevention of cardiovascular disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 4, 2014, Pages

  de Cates, Angharad N ^a   Farr, Matthew R B ^a   Wright, Nicola ^b   Jarvis, Morag C ^a   Rees, Karen ^a   Ebrahim, Shah ^c   Huffman, Mark D ^d  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Public Health Department   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE PLUS ATORVASTATIN; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS LOSARTAN PLUS SIMVASTATIN; ASPIRIN PLUS ATENOLOL PLUS HYDROCHLOROTHIAZIDE PLUS LISINOPRIL PLUS SIMVASTATIN; ASPIRIN PLUS RAMIPRIL PLUS SIMVASTATIN; ATENOLOL; CARDIOVASCULAR AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; SIMVASTATIN; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DRUG COMBINATION; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASE; CAROTID ENDARTERECTOMY; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC BLOOD PRESSURE; DISEASE REGISTRY; FIXED DOSE COMBINATION THERAPY; FRAMINGHAM RISK SCORE; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; THERAPY; TRANSLUMINAL CORONARY ANGIOPLASTY; CARDIOVASCULAR DISEASES; DRUG COMBINATION; META ANALYSIS; MORTALITY; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; HUMANS; PLACEBO EFFECT; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84899029506     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009868.pub2     Document Type: Review

References (98)

1. Pavia LA, Erdine S, Zamorano J, Kim JH, Al KA, Westergaard M, et al.Cardiovascular risk factor management: Single-pill amlodipine/atorvastatin versus usual care in patients with hypertension and additional risk factors - the CRUCIAL trial. Journal of Hypertension 2010;Conference(various pagings):e278-9.
2. Pavia LA, Zamorano J, Kim JH, Erdine S, Al KA, Westergaard M, et al.Treatment strategies for cardiovascular risk factor management in patients with hypertension and additional risk factors-experiences from the usual care arm of the CRUCIAL trial. Journal of Hypertension 2010;Conference(various pagings):e276-7.
3. Zamorano J, Erdine S, Pavia A, Kim JH, Al-Khadra A, Westergaard M, et al.Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: The CRUCIAL trial. Current Medical Research and Opinion 2011;27(4):821-33.
4. Neutel JM, Bestermann WH, Dyess EM, Graff A, Kursun A, Sutradhar S, et al.The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: A randomized, placebo-controlled, multicenter study. Journal of Clinical Hypertension 2009;11(1):22-30.
5. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, et al.A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. International Journal of Clinical Practice 2010;64(9):1220-7.
6. PILL CG. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One 2011;6(5):e19857.
7. Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, et al.A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011;12:3.
8. Indian Polycap Study T, Yusuf S, Pais P, Afzal R, Xavier D, Teo K, et al.Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373(9672):1341-51.
9. Grimm R, Malik M, Yunis C, Sutradhar S, Kursun A, Together I, et al.Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vascular Health & Risk Management 2010;6:261-71.
10. Grimm RH, Malik M, Yunis C, Sutradhar S, Kursun A. The critical importance of treating absolute cardiovascular risk as opposed to individual cardiovascular risk factors in isolation. Journal of Clinical Hypertension 2009;Conference(various pagings):A120-1.
11. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al.Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013;310:918-29. [DOI:].
12. Wald D, Morris J, Wald N. Randomised polypill crossover trial in people aged 50 and over. PLoS One 2012;7(7):e41297.
13. Avenell A, Maclennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, et al.Long-term follow-up for mortality and cancer in a randomized, placebo-controlled trial of vitamin D3 and/or calcium (RECORD). Journal of Clinical Endocrinology and Metabolism 2012;97:614-22.
14. Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, et al.Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. American Journal of Medicine 2012;125:1229e1-10.
15. Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). Journal of Clinical Hypertension 2005;7(5):264-73.
16. Bogger-Meiddo I, Heckbert SR, Weiss NS, McNight B, Furberg CD, Wiggins KL, et al.Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regiments: population-based case-control study. BMJ 2010;340:e303.
17. Ferdinand KC, Flack JM, Saunders E, Victor R, Watson K, Kursun A, et al.Amlodipine/atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. Journal of Clinical Hypertension 2009;11(10):585-93.
18. Flack JM, Victor R, Watson K, Ferdinand KC, Saunders E, Tarasenko L, et al.Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clinics Proceedings 2008;83(1):35-45.
19. Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovascular Disorders 2010;10:29.
20. Chrysant SG. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension. Postgraduate Medicine 2011;123:21-31.
21. Derosa G, Cicero AFG, Carbone A, Querci F, Fogari E, D'Angelo A, et al.Variations of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. Journal of the American Society of Hypertension 2013;7:32-9.
22. Erdine S, Ro YM, Tse HF, Howes LG, Guilar-Salinas CA, Chaves H, et al.Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). Journal of Human Hypertension 2009;23(3):196-210.
23. Hobbs FD, Gensini G, Mancini GB, Manolis AJ, Bauer B, Böhler S, et al.Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). International Journal of Cardiology 2006;110(2):242-50.
24. Richard Hobbs FD, Gensini G, John Mancini GB, Manolis AJ, Bauer B, Genest J, et al.International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. European Journal of Cardiovascular Prevention & Rehabilitation 2009;16(4):472-80.
25. Li M, Xu A, Lam KS, Cheung BM, Tse HF. Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin. Postgraduate Medicine 2011;123:66-71.
26. Liew D, Park HJ, Ko SK. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clinical Therapeutics 2009;31(10):2189-203.
27. Neldam S, Edwards C, Lang M, Jones R. Long-term tolerability and efficacy of single-pill combinations of telmisartan 40-80 mg plus amlodipine 5 or 10 mg in patients whose blood pressure was not initially controlled by amlodipine 5-10 mg: open-label, long-term follow-ups of the TEAMSTA-5 and TEAMSTA-10 studies. Current Therapeutic Research - Clinical and Experimental 2012;73:65-84.
28. Neutel JM, Mancia G, Black HR, Dahlof B, Defeo H, Ley L, Vinisko R, et al.Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. Journal of Clinical Hypertension 2012;14:206-15.
29. Nitsch D, Tomlinson LA. Safety of coprescribing NSAIDs with multiple antihypertensive agents: triple drug combinations are associated with increased hospital admission for acute kidney injury, but questions remain. BMJ 2013;346:e8713.
30. Patel A, Shah T, Shah G, Jha V, Ghosh C, Desai J, et al.Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. American Journal of Cardiovascular Drugs 2010;10(2):95-103.
31. Sun ZB, et al.Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients [Zhonghua xin xue guan bing za zhi]. Chinese Journal of Cardiovascular Disease 2012;40:8-13.
32. Yusuf S, Pais P, Sigamani A, Xavier D, Afzal R, Gao P, Teo KK. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases: The second Indian Polycap Study (TIPS-2) investigators. Circulation: Cardiovascular Quality and Outcomes 2012;5:463-71.
33. Wald DS, Wald NJ. Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the polypill approach. Journal of Evaluation in Clinical Practice 2012;18:612-5.
34. Weber MA, Julius S, Kjeldsen SE, Jia Y, Brunner HR, Zappe DH, et al.Cardiovascular outcomes in hypertensive patients: Comparing single-agent therapy with combination therapy. Journal of Hypertension 2012;30:2213-22.
35. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, et al.Effects of body size and hypertension on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013;381:537-45.
36. Zhu DL, Bays H, Gao P, Mattheus M, Voelker B, Ruilope LM. Efficacy and tolerability of initial therapy with single pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational randomized, double blind, active-controlled trial. Clinical Therapeutics 2012;34:1613-24.
37. Sanz G, Fuster V, Guzmán L, Guglietta A, Arnáiz JA, Martínez F, et al.The fixed-dose combination drug for secondary cardiovascular prevention project: study design and objectives. American Heart Journal 2011;162:811-7.
38. Selak V, Elley CR, Crengle S, Harwood M, Doughty R, Arroll B, et al.Improving adherence using combination therapy (IMPACT): design and protocol of a RCT in primary care. Contemporary Clinical Trials 2011;32:909-15.
39. Liu H, Patel A, Brown A, Eades S, Hayman N, Jan S, et al.Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk. BMC Public Health 2010;10:458.
40. Polypill and non-alcoholic steatohepatitis (PolyIran-L). Clinicaltrials.gov: NCT01245608.
41. Prevention of cardiovascular disease in middle-aged and elderly Iranians using a single polypill (PolyIran). Clinicaltrials.gov: NCT01271985.
42. The International Polycap Study-3. ClinicalTrials.gov Identifier: NCT01646437.
43. ALLHAT-investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.
44. Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, et al.Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010;303(24):2486-94.
45. ATT-Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86.
46. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78.
47. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al.Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60.
48. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. American Journal of Medicine 2007;120:713-8.
49. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, et al.Priority actions for the non-communicable disease crisis. Lancet 2011;377(9775):1438-47.
50. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96.
51. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al.Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693):827-38.
52. Cooney MT, Dudina A, Whincup P, Capewell S, Menotti A, Jousilahti P, et al.Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. European Journal of Cardiovascular Prevention & Rehabilitation 2009;16(5):541-9.
53. Cowie MR. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. International Journal of Clinical Practice 2005;59(7):839-46.
54. Cholesterol Treatment Trialists' Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90. [DOI: ;:].
55. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI:].
56. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
57. Elley CR, Gupta AK, Webster R, Selak V, Jun M, Patel A, et al.The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS One 2012;7:e52145.
58. Franco OH, Bonneux L, de Laet C, Peeters A, Steyerberg EW, Mackenbach JP. The polymeal: a more natural, safer, and probably tastier (than the polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ 2004;329(7480):1447-50.
59. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
60. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 2003;348(5):383-93.
61. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55(2):399-407.
62. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
63. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al.Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011;378(9791):584-94.
64. HPSCG. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
65. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31.
66. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al.Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371(9607):117-25.
67. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 2005;352(14):1425-35.
68. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
69. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010;122(20):2078-88.
70. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, et al.Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. Journal of Clinical Hypertension 2006;8(8):571-81; quiz 82-3.
71. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316, 099 white men. Multiple Risk Factor Intervention Trial Research Group. Archives of Internal Medicine 1992;152(1):56-64.
72. NICE. Lipid Modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. http://www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf 2008.
73. NICE. Prevention of cardiovascular disease at population level. http://www.nice.org.uk/guidance/PH25 2010.
74. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. Journal of the American College of Cardiology 2004;43(11):2142-6.
75. Ostergren J, Poulter NR, Sever PS, Dahlof B, Wedel H, Beevers G, et al.The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. Journal of Hypertension 2008;26(11):2103-11.
76. Papademetriou V, Piller LB, Ford CE, Gordon D, Hartney TJ, Geraci TS, et al.Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension 2003;5(6):377-84.
77. Perk J, DeBacker G, Gohlke H, et al.European Guidelines on cardiovascular diseaseprevention in clinical practice (version 2012). European Journal of Cardiology 2012;33:1635-701. [PUBMED: 10.1093/eurheartj/ehs092].
78. PILL-collaborative, Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, et al.An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. Plos One 2011;6(5):e19857.
79. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F, et al.A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. Journal of Clinical Pharmacology 2007;47(12):1555-69.
80. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34(11):2741-8.
81. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58.
82. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013;Nov 12:[Epub ahead of print].
83. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al.Statins for the primary prevention of cardiovascular disease.. Cochrane Database of Systematic Reviews 2013;1:CD004816.
84. Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young. European Heart Journal 2002;23(7):528-35.
85. The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373:1341-51.
86. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35.
87. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Mannisto S, Sundvall J, et al.Thirty-five-year trends in cardiovascular risk factors in Finland. International Journal of Epidemiology 2010;39(2):504-18.
88. Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD. Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Preventive Medicine 2011;52(1):10-5.
89. Virdee SK, Greenfield SM, Fletcher K, McManus RJ, Hobbs FD, Mant J. Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open 2013;3:e002498.
90. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326(7404):1419.
91. Wald DS, Wald NJ. The polypill in the prevention of cardiovascular disease. Preventive Medicine 2011;52(1):16-7.
92. World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. Report of WHO-Wellcome Trust meeting of experts (1-3 August 2001). Geneva: World Health Organization 2002.
93. World Health Organization. Global Health Observatory Data Respository. Available from http://apps.who.int/ghodata. Accessed on 02/01/2012.
94. World Health Organization. Global status report on noncommunicable diseases. Geneva: World Health Organization, 2010 (a).
95. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization 2011.
96. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360(9326):2-3.
97. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52.
98. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al.Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 2011;378(9798):1231-43.